Chidozie Ugwumba - Jun 16, 2023 Form 4 Insider Report for Clene Inc. (CLNN)

Role
Resigned as director 2/15/2023, 10%+ Owner
Signature
/s/Chidozie Ugwumba
Stock symbol
CLNN
Transactions as of
Jun 16, 2023
Transactions value $
$6,000,000
Form type
4
Date filed
9/8/2023, 04:33 PM
Previous filing
Jun 8, 2023
Next filing
Oct 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLNN Common Stock Purchase $6M +7.5M +135.9% $0.80 13M Jun 16, 2023 By Symbiosis II, LLC F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLNN Warrants (Right to buy) Award +7.5M 7.5M Jun 16, 2023 Common Stock 7.5M $1.50 By Symbiosis II, LLC F1, F2
transaction CLNN Warrants (Right to buy) Award +7.5M 7.5M Jun 16, 2023 Common Stock 7.5M $1.10 By Symbiosis II, LLC F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price for each Unit is $0.80; one Unit consists of one share of Common Stock of Clene, one Tranche A Warrant and one Tranche B Warrant.
F2 The reporting person purchased a unit consisting of one share of Common Stock of Clene Inc., one Tranche A Warrant, and one Tranche B Warrant. The Tranche B Warrant is for 7,500,000 shares of Common Stock of Clene Inc. at an exercise price of $1.50 per share. The Tranche B Warrant will expire on the earlier of (a) June 16, 2030, or (b) 60 days after the Food and Drug Administration accepts a New Drug Application from Clene Inc.
F3 The reporting person purchased a unit consisting of one share of Common Stock of Clene Inc., one Tranche A Warrant, and one Tranche B Warrant. The Tranche A Warrant is for 7,500,000 shares of Common Stock of Clene Inc. at an exercise price of $1.10 per share. The Tranche A Warrant will expire on the earlier of (a) June 16, 2026, or (b) 60 days after the Food and Drug Administration accepts a New Drug Application from Clene Inc.